Figure 6 from Effect on Hemoglobin A1c (HbA1c) and Body Weight After ...

FIGURE 6 : Change in body weight at two, four, and six months after drug discontinuation - " Effect on Hemoglobin A1c ( HbA1c ) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose-Dependent Insulinotropic Peptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Single-Center Case Series Study"

Fifty-two weeks after randomization, study drug administration was discontinued. To investigate progress after the end of administration, changes in hemoglobin A1c ( HbA1c ) and body weight were further examined two, four, and six months after discontinuation of the study drug.
Effect on Hemoglobin A1c (HbA1c) and Body Weight After ...

To investigate progress after the end of administration, changes in hemoglobin A1c ( HbA1c ) and body weight were further examined two, four, and six months after discontinuation of the study drug. Results After fifty-two weeks, all tirzepatide groups had improved HbA1c and body weight compared with the dulaglutide group.
Co-primary outcomes were weight loss of 15 kg or more, and remission of diabetes, defined as glycated haemoglobin ( HbA1c ) of less than 6ยท5% (<48 mmol/mol) after at least 2 months off all ...

Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation ...
Clinical trials have shown that tirzepatide significantly reduces HbA1c levels and induces substantial weight reduction, and this work reports two cases of diabetes remission after temporary tirzepatide therapy.
The duration of the off-drug treatment period was 4 weeks, which is not enough to affect HbA1c and body weight fully or determine the long-term effects of discontinuing tirzepatide treatment.

Hemoglobin A1c Reduction With the GLP
This post hoc analysis assessed the HbA1c -lowering efficacy of semaglutide, a GLP-1RA, in participants with a range of kidney functions in the SUSTAIN 4-6 and 10 (subcutaneous semaglutide) and PIONEER 5 and 6 (oral semaglutide) clinical trials. Trial-level changes from baseline to end of treatment (EOT) in HbA1c and body weight (BW) were assessed in participants with estimated glomerular ...
Figure 3 shows changes in HbA1c over the course of the trial and two years after drug discontinuation. Two months after discontinuing tirzepatide, re-elevation of HbA1c was observed ( Figure 3). ...
Effects of Glucagon
Iqbal J, Wu HX, Hu N, et al. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.








Recommendation 2.2.1: We recommend an individualized HbA1c target ranging from <6.5% to <8.0% in people with diabetes and CKD not treated with dialysis ( Figure 10) (1C).